Yusuke Nakamura to Combined Modality Therapy
This is a "connection" page, showing publications Yusuke Nakamura has written about Combined Modality Therapy.
Connection Strength
0.165
-
A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors. PLoS One. 2018; 13(1):e0187878.
Score: 0.030
-
Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J Transl Med. 2014 Apr 03; 12:84.
Score: 0.023
-
Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 2012 Oct; 41(4):1297-304.
Score: 0.021
-
Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2010 Feb; 101(2):433-9.
Score: 0.017
-
Serum REG4 level is a predictive biomarker for the response to preoperative chemoradiotherapy in patients with pancreatic cancer. Pancreas. 2009 Oct; 38(7):791-8.
Score: 0.017
-
[Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer]. Gan To Kagaku Ryoho. 2008 Nov; 35(12):2268-70.
Score: 0.016
-
[A phase I study of combination-therapy with gemcitabine and epitope peptides derived from human vascular endothelial growth factor receptor for unresectable or recurrent pancreas cancer]. Gan To Kagaku Ryoho. 2008 Nov; 35(12):2271-3.
Score: 0.016
-
[A case of inoperable gastric small cell carcinoma effectively treated by chemotherapy and radiotherapy]. Gan To Kagaku Ryoho. 2006 Jul; 33(7):977-9.
Score: 0.014
-
Prediction of outcome of advanced cervical cancer to thermoradiotherapy according to expression profiles of 35 genes selected by cDNA microarray analysis. Int J Radiat Oncol Biol Phys. 2004 Sep 01; 60(1):237-48.
Score: 0.012